Stock Track | Avita Therapeutics Soars 14.18% Intraday on Positive Interim Wound Care Study Results

Stock Track
04/15

Avita Therapeutics' stock soared 14.18% intraday following the release of positive interim data from a key clinical study.

The surge comes after the company reported interim results from its Cohealyx-I multi-center study, which showed a significant reduction in the mean time to skin grafting for patients with full-thickness wounds. The data indicated a mean time of 13.6 days compared to a 33.2-day real-world benchmark.

The positive clinical outcomes, including a median time to grafting of 11 days, are seen as a promising development for the company's wound care platform, driving investor optimism regarding its potential market application and future commercial success.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10